January 15, 2026 - PRESSADVANTAGE - Lucent Vision has published a new educational resource titled “What Practice Offers ...

SpyGlass Pharma is pursuing a $100 million IPO to advance its glaucoma drug delivery platform through Phase 3 trials. Read ...

SpyGlass Pharma has randomized the first patients in its 2 registrational phase 3 clinical trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL System) for the lowering of intraocular pressure (IOP) ...

SpyGlass Pharma, a late-stage biopharmaceutical company, today announced that the first patients have been randomized in two registrational Phase III clinical trials of its lead product candidate, the ...

In this Healio Video Perspective from Hawaiian Eye 2026, Michael Greenwood, MD, of Vance Thompson Vision, discusses the InSightVR system from GreenMan.InSightVR is a virtual reality tool that shows ...

Using neutral language with patients and thorough documentation can help mitigate your practice’s legal risks when utilizing ...

In an extraordinary display of resilience, a Trenance Manor pupil defied health challenges to shine in his matric exams, ...

After a public plea for help, Elizabeth Williams, a 77-year-old woman suffering from vocal cord palsy, is finally scheduled ...

The BIM-IOL is designed to be implanted during cataract surgery, tackling IOP while restoring vision, and SpyGlass is also ...

Immunology biotech Agomab Therapeutics and eye-focused SpyGlass Pharma have both unveiled their intentions to go public, in ...

Johnson & Johnson (NYSE:JNJ) Q4 2025 Earnings Call Transcript January 21, 2026 Johnson & Johnson reports earnings inline with ...

WALTHAM, Mass., Jan. 19, 2026 (GLOBE NEWSWIRE) -- BVI, a global leader in the ophthalmic device market, announced today the appointment of Jim Hollingshead as President & Chief Executive Officer.